Barclays sees European chemicals at peak cycle; upgrades Wacker, Solvay, cuts Clariant
** Barclays says chemicals are around their peak cycle with fundamentals set to weaken through 2027, although Middle East disruption has supported pricing
** It sees supply tightness supporting earnings through Q4 and into Q1 2027, delaying rather than preventing the downturn, with more caution from Q2, as companies "begin to lap stronger volume comparatives and tougher comparatives from the onset of the conflict"
** Q3 was a pricing quarter rather than a volume quarter, the broker says, with pricing accelerating from -2% yoy in Q1 to +7% in Q3 and beating expectations across most diversified chemicals, while volumes generally slowed versus Q2
** Barclays raises Solvay SOLB.BR to "equal weight" from "underweight" and its PT to €24 from €20, citing potential OneIM rare-earths JV with gross cash proceeds which could reduce leverage, stopping "short of 'overweight' given continued FCF/dividend risk"
** The broker raises Wacker Chemie WCHG.DE to "overweight" from "equal weight", as it believes that FY 2027 expectations, asymmetric polysilicon optionality and EU silicones tailwind create an attractive setup
** It however cuts Clariant CLN.S to "equal weight" from "overweight", on renewed litigation risk not reflected in the shares, questioning FY 2027 expectations and Ashland deal risks